Search
Novo Nordisk A/S
NVOAdd to Watchlist
43.190USD
-0.325-0.75%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
145.51BMarket Cap
10.10P/E TTM
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Total GLP-1
23.00B
49.25%
Obesity (Saxenda®)
12.44B
26.64%
Long-acting insulin
2.83B
6.07%
Fast-acting insulin
2.81B
6.01%
Rare blood disorders
1.81B
3.87%
Other
3.81B
8.16%
By RegionUSD
Name
Revenue
Proportion
USA
26.17B
56.03%
EUCAN
9.99B
21.38%
Emerging Markets
4.60B
9.85%
APAC
3.13B
6.70%
Region China
2.82B
6.04%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Total GLP-1
23.00B
49.25%
Obesity (Saxenda®)
12.44B
26.64%
Long-acting insulin
2.83B
6.07%
Fast-acting insulin
2.81B
6.01%
Rare blood disorders
1.81B
3.87%
Other
3.81B
8.16%
